Resistance to Tyrosine Kinase Inhibitors / edited by Daniele Focosi.
Contributor(s): Focosi, Daniele, editor literario
Material type:
E-bookSeries: Resistance to Targeted Anti-Cancer TherapeuticsPublisher: Cham, Switzerland : Springer, 2016Description: 1 recurso en línea (XIII, 188 p.) : 8 ilustraciones, 6 ilustraciones en color.ISBN: 9783319460918.Subject: Resistencia a los medicamentos
| Item type | Current library | Collection | Call number | Copy number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC271.P76 R475 2016 EB (Browse shelf(Opens below)) | .i11603720 | Acceso electrónico | eBOOK .i11603720 |
Browsing Madrid Digital shelves, Shelving location: Acceso Electrónico (UEM) Close shelf browser (Hides shelf browser)
| RC271.P74 R448 2006 EB Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PCs) : A New Potential Strategy in Cancer Therapy | RC271 .P74 R47 2014 EB Resistance to Proteasome Inhibitors in Cancer : Molecular Mechanisms and Strategies to Overcome Resistance | RC271.P76 F333 2006 EB Protein Tyrosine Kinases : From Inhibitors to Useful Drugs | RC271.P76 R475 2016 EB Resistance to Tyrosine Kinase Inhibitors | RC271 .R26 2011 EB Targeted radionuclide therapy | RC271 .R27 2007 EB Brachytherapy : applications and techniques | RC271 .R27 2019 EB Brachytherapy : Techniques and Evidences |
Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
There are no comments on this title.